Kintara Therapeutics Shares Plumb New Depths on VAL-083 Failure
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
About 62% of Kintara Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Kintara Therapeutics suggests that many traders are alarmed regarding Kintara Therapeutics' prospects. The current market sentiment, together with Kintara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Kintara Therapeutics stock news signals to limit their universe of possible portfolio assets.
Kintara |
By Colin Kellaher Kintara Therapeutics shares crumbled to an all-time low Tuesday following the failure of the biopharmaceutical companys lead product...
Read at marketwatch.com
 |
Kintara Therapeutics Fundamental Analysis
We analyze Kintara Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Kintara Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Kintara Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kintara Therapeutics stock to make a market-neutral strategy. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics with similar companies.
Peers
Kintara Therapeutics Related Equities
| ONCY | Oncolytics Biotech | 1.85 | ||||
| MCRB | Seres Therapeutics | 1.59 | ||||
| SCPH | Scpharmaceuticals | 0.31 | ||||
| LUMO | Lumos Pharma | 0.23 | ||||
| SLRX | Salarius Pharmaceuticals | 0.00 | ||||
| MIST | Milestone Pharmaceuticals | 0.00 | ||||
| LSTA | Lisata Therapeutics | 0.00 | ||||
| TOVX | Theriva Biologics | 0.85 | ||||
| CLRB | Cellectar Biosciences | 0.88 | ||||
| VCNX | Vaccinex | 1.08 | ||||
| DMAC | DiaMedica Therapeutics | 1.30 | ||||
| GOVX | GeoVax Labs | 2.55 | ||||
| BOLT | Bolt Biotherapeutics | 2.83 | ||||
| SABS | SAB Biotherapeutics | 2.94 | ||||
| DYAI | Dyadic International | 8.59 | ||||
| FBRX | Forte Biosciences | 18.10 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |